Bintrafusp alfa治疗铂类失败后复发或转移性宫颈癌:一项非随机对照试验
这项2期非随机对照试验评估bintrafusp alfa单药治疗铂类化疗期间或之后进展的复发或转移性宫颈癌患者的安全性和缓解率。203例筛查患者中146例接受至少1剂bintrafusp alfa 1200 mg每2周静脉给药,确认客观缓解率为21.9%(95%CI 15.5-29.5),达到主要终点。
要点
- 确认客观缓解率21.9%(95%CI 15.5-29.5),95%CI下限高于15%的基准。
- 32例缓解者中19例(59.4%)缓解持续6个月或以上,数据截止时13例(40.6%)缓解仍在持续。
- 最常见治疗相关不良事件为贫血25例(17.1%)、皮疹21例(14.4%)、甲状腺功能减退15例(10.3%)、瘙痒15例(10.3%)。
核心结论
- 该2期非随机对照试验达到主要终点,可能支持靶向转化生长因子β和程序性细胞死亡配体1的双特异性疗法在复发或转移性宫颈癌患者中的潜力。
研究设计与样本
- 2期非随机对照试验,评估bintrafusp alfa单药治疗铂类化疗期间或之后疾病进展的复发或转移性宫颈癌患者。
- 数据收集时间为2020年3月至2022年2月。
- 203例筛查患者中146例接受至少1剂bintrafusp alfa,中位(范围)年龄53(24-79)岁。
- 干预为bintrafusp alfa 1200 mg静脉给药,每2周一次。
- 主要终点为独立审查委员会根据实体瘤疗效评价标准版本1.1确认的客观缓解率。
主要发现
- 确认客观缓解率为21.9%(95%CI 15.5-29.5),95%CI下限高于15%的客观缓解率基准。
- 32例缓解者中19例(59.4%)缓解持续6个月或以上。
- 数据截止时,32例缓解者中13例(40.6%)缓解仍在持续。
- 最常见治疗相关不良事件为贫血25例(17.1%)、皮疹21例(14.4%)、甲状腺功能减退15例(10.3%)、瘙痒15例(10.3%)。
- 任何原因的特殊关注不良事件包括贫血82例(56.2%)、出血事件81例(55.5%)、免疫相关不良事件49例(33.6%)。
关键数值与推荐
- 确认客观缓解率21.9%(95%CI 15.5-29.5),按独立审查委员会评估。
- 客观缓解率基准为15%,主要终点要求95%CI下限高于该基准。
- 32例缓解者中19例(59.4%)缓解持续6个月或以上,数据截止时13例(40.6%)缓解仍在持续。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming growth factor β trap) fused via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed cell death 1 ligand 1. OBJECTIVE: To evaluate the safety and response rates of bintrafusp alfa in patients with recurrent or metastatic cervical cancer. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 nonrandomized controlled trial evaluated bintrafusp alfa monotherapy in patients with recurrent or metastatic cervical cancer with disease progression during or after platinum-based chemotherapy. Data were collected from March 2020 to February 2022. INTERVENTION: Patients received bintrafusp alfa, 1200 mg, intravenously once every 2 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by an independent review committee. RESULTS: At data cutoff, 146 of 203 screened patients received 1 or more doses of bintrafusp alfa; of these, the median (range) age was 53 (24-79) years. The study met its primary end point of a 95% CI above the objective response rate benchmark of 15%, with a confirmed objective response rate of 21.9% (95% CI, 15.5-29.5) per the independent review committee. Of these patients, 19 (59.4%) had a durable response of 6 months or more. At data cutoff, responses were ongoing in 13 of 32 responders (40.6%). The most common treatment-related adverse events were anemia (25 [17.1%]), rash (21 [14.4%]), hypothyroidism (15 [10.3%]), and pruritus (15 [10.3%]). Any-cause adverse events of special interest included anemia (82[56.2%]), bleeding events (81 [55.5%]), and immune-related adverse events (49 [33.6%]). CONCLUSIONS AND RELEVANCE: This phase 2 nonrandomized controlled trial of bintrafusp alfa met its primary end point, which may support the potential of a bispecific therapy targeting transforming growth factor β and programmed cell death 1 ligand 1 in patients with recurrent or metastatic cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04246489.
引用
- Birrer M, Li G, Yunokawa M, et al. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 39052242. doi:10.1001/jamaoncol.2024.2145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。